Core Viewpoint - The successful development of the HiTS 200 light ion therapy device marks a significant breakthrough in China's advanced cancer treatment equipment sector, offering more precise and efficient treatment options for cancer patients [1][2]. Group 1: Product Development - The HiTS 200 light ion therapy device, developed by Guoke Ion (Hangzhou) Medical Technology Co., Ltd., has completed production and initial adjustments in Lanzhou, with installation and debugging at the Hangzhou research center, and is set to begin beam debugging [1]. - This device integrates multiple ion beam treatment capabilities, including proton, helium, and carbon ion beams, and has the potential for proton CT imaging, enabling more accurate localization and treatment [1][2]. Group 2: Cost and Accessibility - Compared to traditional heavy ion therapy equipment, the HiTS 200 occupies only 1,500 square meters, significantly reducing equipment and construction costs, making it more suitable for implementation in municipal medical institutions [2]. - The device's design allows for flexible treatment plans based on the tumor's location and nature, enhancing accessibility to advanced cancer treatment [2]. Group 3: Technological Advancements - The HiTS 200 features advanced technologies such as rapid ion switching, single-cycle energy variation, rapid repeated scanning, and Flash dose delivery, which contribute to its core advantages [2]. - By integrating the self-developed Phoenix treatment planning system, the HiTS 200 can achieve multi-ion combined therapy, allowing for personalized radiotherapy plans tailored to different lesions [2]. Group 4: Industry Impact - The successful development of the first light ion therapy device fills a gap in China's multi-ion integrated treatment equipment sector, potentially advancing the country's radiation therapy technology from conventional to precision and personalized treatment [2]. - The industrialization of this device is expected to significantly lower the costs of high-end ion therapy for cancer patients in China, promoting equitable access and enhancing the international competitiveness of China's medical equipment [2].